BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Trexquant Investment LP

Trexquant Investment LP lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 43.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 494,356 shares of the biotechnology company’s stock after selling 386,635 shares during the quarter. Trexquant Investment LP’s holdings in BioCryst Pharmaceuticals were worth $3,718,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Venturi Wealth Management LLC purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $46,000. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $48,000. KBC Group NV lifted its position in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares during the last quarter. Raymond James Financial Inc. purchased a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $80,000. Finally, Quantinno Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals during the third quarter valued at about $82,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $6.83 on Monday. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -11.20 and a beta of 1.84. The stock’s 50-day moving average is $8.14 and its two-hundred day moving average is $7.80. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The business’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 EPS. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on BCRX shares. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.